A small trial of brentuximab vedotin given concurrently with rituximab for patients with de novo immunosuppression-associated CD30-positive and/or EBV-positive lymphomas included 12 PTLD after solid organ transplantation [33]. Here, TNFRSF8 is linked to post-transplant lymphoproliferative disease.